Pipeline

RUO*

CLIA LDT

FDA-Cleared IVD

Multiple Myeloma

RUO*

CLIA LDT

FDA-Cleared IVD

Bone Marrow (BM)

Peripheral Blood (PB)

Plasma (ctDNA)

Acute Lymphoblastic Leukemia

RUO*

CLIA LDT

FDA-Cleared IVD

BM

PB

Plasma (ctDNA)

Chronic Lymphocytic Leukemia

RUO*

CLIA LDT

FDA-Cleared IVD

BM, PB

Plasma (ctDNA)

Diffuse Large B-cell Lymphoma

RUO*

CLIA LDT

FDA-Cleared IVD

Plasma (ctDNA), BM, PB

Other Non-Hodgkin’s Lymphoma
(e.g. FL, MCL)

RUO*

CLIA LDT

FDA-Cleared IVD

BM, PB

Plasma (ctDNA)

Other Lymphoid Malignancies

RUO*

CLIA LDT

FDA-Cleared IVD

BM, PB

Plasma (ctDNA)

¹ Available to order as a CLIA-validated laboratory developed test (LDT) service. This use has not been cleared or approved by the FDA.

clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary